WO2002051865A3 - Proteinic antigens inducing antibodies neutralising hiv virus - Google Patents

Proteinic antigens inducing antibodies neutralising hiv virus Download PDF

Info

Publication number
WO2002051865A3
WO2002051865A3 PCT/FR2001/003957 FR0103957W WO02051865A3 WO 2002051865 A3 WO2002051865 A3 WO 2002051865A3 FR 0103957 W FR0103957 W FR 0103957W WO 02051865 A3 WO02051865 A3 WO 02051865A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv virus
inducing antibodies
proteinic
antigens inducing
antibodies neutralising
Prior art date
Application number
PCT/FR2001/003957
Other languages
French (fr)
Other versions
WO2002051865A2 (en
Inventor
Veronique Barban
Original Assignee
Aventis Pasteur
Veronique Barban
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0016986A external-priority patent/FR2818648B1/en
Application filed by Aventis Pasteur, Veronique Barban filed Critical Aventis Pasteur
Priority to AU2002219290A priority Critical patent/AU2002219290A1/en
Publication of WO2002051865A2 publication Critical patent/WO2002051865A2/en
Publication of WO2002051865A3 publication Critical patent/WO2002051865A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention concerns a proteinic antigen of formula P-E-S wherein: P represents a protein or a carrier peptide or a fragment derived therefrom; E represents a spacer arm of 2 to 25 amino acids, mainly consisting of glycine, proline or alanine; S represents a specific peptide sequence, said antigen being capable of inducing neutralising antibodies against HIV primary isolates and its use in an anti-HIV vaccine.
PCT/FR2001/003957 2000-12-22 2001-12-12 Proteinic antigens inducing antibodies neutralising hiv virus WO2002051865A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002219290A AU2002219290A1 (en) 2000-12-22 2001-12-12 Proteinic antigens inducing antibodies neutralising hiv virus

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0016986A FR2818648B1 (en) 2000-12-22 2000-12-22 PROTEIN ANTIGENS INDUCING HIV VIRUS NEUTRALIZING ANTIBODIES
FR00/16986 2000-12-22
US26481901P 2001-01-26 2001-01-26
US60/264,819 2001-01-26

Publications (2)

Publication Number Publication Date
WO2002051865A2 WO2002051865A2 (en) 2002-07-04
WO2002051865A3 true WO2002051865A3 (en) 2002-09-12

Family

ID=26212802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/003957 WO2002051865A2 (en) 2000-12-22 2001-12-12 Proteinic antigens inducing antibodies neutralising hiv virus

Country Status (2)

Country Link
AU (1) AU2002219290A1 (en)
WO (1) WO2002051865A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070073754A (en) * 2004-09-03 2007-07-10 아마테라스파마 가부시키가이샤 Anti-histone h1 monoclonal antibody and hybridoma capable of producing the same
BR112018008221A2 (en) * 2015-10-26 2018-10-30 Basf Se methods of bonding or bleaching enamel and / or dentin, repairing or inhibiting dental erosion, promoting dental remineralization, and / or enhancing the anti-cavity effects of fluoride and producing an oral care product comprising habp, dentifrice. use of habp in the manufacture of an oral care composition, oral care composition comprising habp, hydroxyapatite binding polypeptide, and chewing gum composition.
WO2017072103A1 (en) * 2015-10-26 2017-05-04 Basf Se Oral care products and methods comprising hlps

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035194A2 (en) * 1996-03-21 1997-09-25 President And Fellows Of Harvard College Enantiomeric screening process, and compositions therefor
WO1999066046A1 (en) * 1998-06-12 1999-12-23 Aventis Pasteur Hiv virus mimotopes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035194A2 (en) * 1996-03-21 1997-09-25 President And Fellows Of Harvard College Enantiomeric screening process, and compositions therefor
WO1999066046A1 (en) * 1998-06-12 1999-12-23 Aventis Pasteur Hiv virus mimotopes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FOMSGAARD A ET AL.: "Improved Humoral and Cellular Immune Responses Against the gp120 V3 Loop of HIV-1 Following Genetic Immunization with a Chimeric DNA Vaccine Encoding the V3 Inserted into the Hepatitis B Surface Antigen", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 47, 1998, pages 289 - 295, XP002181537 *

Also Published As

Publication number Publication date
AU2002219290A1 (en) 2002-07-08
WO2002051865A2 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
ZA912305B (en) Novel vaccine
KR910016343A (en) Serum Reactive Epitopes of Human Papillomavirus (HPV) 16 Protein
IL102687A0 (en) Method for enhancing immunogenicity
ATE366313T1 (en) ANTIGEN PEPTIDES FROM NEISSERIA
DK1278534T3 (en) Methods and compositions for attenuating the multiplication of HIV-1
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
MXPA04000597A (en) Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine.
EP2298793A3 (en) Polypeptide fragments of hepatitis E virus, vaccine composition comprising said fragments and diagnostic kits
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
GB9401987D0 (en) Modified nucleic acid
NZ535908A (en) HIV regulatory and auxilliary peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
DK0491628T3 (en) Lipopeptides inducing cytotoxic T lymphocytes and their use as vaccines
WO2003015702A3 (en) Epitopes of human immunodeficiency virus-1
WO2002051865A3 (en) Proteinic antigens inducing antibodies neutralising hiv virus
CA2521038A1 (en) Polypeptide comprising cell adhesion motif, t cell epitope and b cell epitope for inducing antibody production
CA2338886A1 (en) Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
EP1342727A4 (en) Antibody against norwalk virus and method of detecting virus by using the antibody
WO2004056316A3 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
WO2007129218A3 (en) Tpeptides for detecting or inducing production of antibodies against human papilloma virus, l1 protein or peptides from this protein.
WO2003064446A3 (en) Plasma protein-binding peptides from bacterial curli
WO2001093804A3 (en) Hepatitis c virus conjugates
WO2005062871A3 (en) Tat linear epitope peptides and conjugates thereof for use in therapeutic compositions and assays
RU2000106709A (en) GP41 PROTEIN EPITOPE PEPTIDES IMITATORS OF HUMAN IMMUNO DEFICIENCY VIRUS TYPE 1 RECOGNIZED BY 2F5 VIRAL NEUTRALIZING MONOCLONAL ANTIBODIES
Ivanoff et al. Human immunodeficiency virus antigen.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP